LESLIE BRADY

Policies related to PBM and drug cost transparency Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.2381/S. 1866) Policies related to the availability and patient awareness of breast cancer risk assessments H.R. 4541, the EARLY Act Reauthorization of 2025 Issues related to the US Preventive Services Task Force Policies related to the impact of tariffs on the availability of silicone prosthetics National Breast Cancer Awareness Month Breast Cancer Research Stamp Reauthorization Act (H.R. 8358) Breast Cancer Stamp Reauthorization Act (S.4318) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-GRAIL, Inc. Galleri (Docket No. FDA-2026-N-8004) Proposed Rule on Regulation for Federal Financial Assistance (OMB-2026-0034)

Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3037/S.1500); a bill prohibiting group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations Implementation of the Affordable Care Act Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Policies related to coverage of preventive services with no cost-sharing Protect patients from substandard and junk insurance products Implementation of One Big Beautiful Bill Act (H.R.1) Policies related to coverage for breast cancer treatments, including breast or chest wall surgical reconstructions HELP Copays Act (S. 864, H.R. 6423) Excepted Fertility Benefits Proposed Rules (1210-AC40)

Potential legislation on hospital emergency department care of people with sickle cell disease Education and support for Congressional Sickle Cell Disease Caucus

Medicare coverage policy for breast cancer treatments and services Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Medicare coverage policy for drugs and drug pricing Medicare Drug Pricing Negotiation implementation Preserving and expanding access to Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act H.R. 2048, Metastatic Breast Cancer Access to Care Act Submission of Information about Selected Drugs and Their Therapeutic Alternatives for Medicare Drug Price Negotiation Comments on CMS-5546-P: Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model Comments on RE: CMS-5545-P: Global Benchmark for Efficient Drug Pricing (GLOBE) Model

Policies related to PBM and drug cost transparency Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.2381/S. 1866) Policies related to the availability and patient awareness of breast cancer risk assessments H.R. 4541, the EARLY Act Reauthorization of 2025 Comments RE: HHS Health Sector AI RFI Comments RE: Solicitation of Proposals for New and Modified Safe Harbors and Special Fraud Alerts OIG-1125-N, (Annual Solicitation)

Blood and plasma safety and awareness Bleeding disorders awareness

Funding for federal hemophilia programs in FY26 and FY27 House and Senate Labor-HHS Appropriations bills NIH FY26 and FY27 appropriations

Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of the Affordable Care Act The HELP Copays Act (S. 864, H.R. 6423) Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model Policies related to copay accumulator adjustor and maximizer programs Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46, HR 1834 Comments on Proposed Rule: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P)

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 1796/S. 735)

Medicare coverage policy for breast cancer treatments and services Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Medicare coverage policy for drugs and drug pricing Medicare Drug Pricing Negotiation implementation Preserving and expanding access to Medicaid H.R. 1, One Big Beautiful Bill Act H.R. 2048, Metastatic Breast Cancer Access to Care Act

Policies related to PBM and drug cost transparency Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.2381/S. 1866) Policies to support National Breast Cancer Awareness Month

Funding for federal hemophilia programs in FY26 House and Senate Labor-HHS Appropriations bills NIH FY26 appropriations

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Hemophilia research, prevention, surveillance and service programs and issues

H.R. 1, One Big Beautiful Bill Act Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46.

Medicare coverage policy for breast cancer treatments and services Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Medicare coverage policy for drugs and drug pricing Medicare Drug Pricing Negotiation implementation Preserving and expanding access to Medicaid H.R. 1, One Big Beautiful Bill Act Comments RE: Proposed Rule on Medicare and Medicaid Programs; CY 2026 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program Policies related to inclusion of new ICD-10 codes for inflammatory breast cancer and the coverage of External Breast Prostheses in Medicare

Funding for federal hemophilia programs in FY26 House and Senate Labor-HHS Appropriations bills NIH FY26 appropriations

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Hemophilia research, prevention, surveillance and service programs and issues

Medicare coverage policy for breast cancer treatments and services Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Medicare coverage policy for drugs and drug pricing Medicare Drug Pricing Negotiation implementation Preserving and expanding access to Medicaid H.R. 1, One Big Beautiful Bill Act

Access to clinical trials for underrepresented populations Policies related to PBM and drug cost transparency Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.2381/S. 1866) Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices Policies related to rapid and large-scale reductions-in-force (RIFs) and reorganizations of departments Comments RE: Re: Request for Information Regarding the Prescription Drug Machine-Readable File Requirement in the Transparency in Coverage Final Rule

Letter to Secretary Kennedy regarding the reductions in force at the Centers for Disease Control and Preventions Division of Blood Disorders and Public Health Genomics Funding for federal hemophilia programs in FY25 House and Senate Labor-HHS Appropriations bills NIH FY25 appropriations

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Hemophilia research, prevention, surveillance and service programs and issues

H.R. 1, One Big Beautiful Bill Act

Medicare coverage policy for breast cancer treatments and services Policies related to funding, state incentives, and federal efforts for Medicaid expansion Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Policies related to Medicare coverage for pharmacy services Medicare coverage policy for drugs and drug pricing Medicare Drug Pricing Negotiation implementation Preserving and expanding access to Medicaid Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly proposed rule outlining revisions to Medicare Advantage (MA) and Medicare Part D for Contract Year 2026. Medicare Multi-Cancer Early Detection Screening Coverage Act (HR 842/S 339); a bill to provide for Medicare coverage of multi-cancer early detection screening tests.

Access to clinical trials for underrepresented populations Policies related to cancer survivorship Policies related to medications access during emergencies Polices related to PBM and drug cost transparency Policies related to reducing the cost of cancer treatment for patients Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.2381) Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices, Comments in response to proposed updates to HRSA-Supported Womens Preventive Services Guidelines Policies to remove the notice and comment process for a wide array of agency actions Policies related to rapid and large-scale reductions-in-force (RIFs) and reorganizations of departments

Funding for federal hemophilia programs in FY25 House and Senate Labor-HHS Appropriations bills NIH FY25 appropriations

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Hemophilia research, prevention, surveillance and service programs and issues Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (H.R. 1796/S. 735)

Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851/S. 2464) Safe Step Act (H.R.2630/S. 652) Implementation of the Affordable Care Act HELP Copays Act (H.R.830/S.1375) Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging Find It Early Act (H.R.3086/S.5141) Policies related to coverage of preventive services with no cost-sharing Polices regarding White House Cancer Moonshot implementation Policies related to copay accumulator and maximizer adjustors Policies related to the extension of enhanced advanced premium tax credits Healthcare Affordability Act of 2024 (H.R. 9774 / S. 5194) H.R. 1692 - Health Care Affordability Act of 2023; S. 8 - Improving Health Insurance Affordability Act of 2023 Letter to tri-agencies (Department of Health and Human Services, Treasury, Labor) re Enhancing Coverage of Preventive Services Under the Affordable Care Act Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2026; and Basic Health Program (CMS-9888-P) House Ways and Means Committee Request for Information - Tax Priorities Protect patients from substandard and junk insurance products

Metastatic Breast Cancer Access to Care Act (S. 663 / HR 549) Medicare coverage policy for breast cancer treatments and services Telehealth Policies related to funding, state incentives, and federal efforts for Medicaid expansion Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Policies related to Medicare coverage for pharmacy services Medicare coverage policy for drugs and drug pricing H.R.3086/S.5141 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Medicaid unwinding, the process for redetermination of Medicaid eligibility Medicare Drug Pricing Negotiation implementation Preserving and expanding access to Medicaid Community Health Worker Access Act which is a bill to amend titles XVIII and XIX of the Social Security Act to increase access to community health workers under the Medicare and Medicaid programs (S. 3892)

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Blood and plasma safety and awareness Bleeding disorders awareness Securing Equal Access to Research, Care, and Health (SEARCH) Act Creating Hope Reauthorization Act of 2024 (HR 7384)

Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Issues related to 1115 Waivers in Medicaid Preserving and expanding access to Medicaid Providing Realistic Opportunity to Equal and Comparable Treatment (PROTECT) for Rare Act (H.R. 6094) The Menstrual Equity for All Act (H.R. 3646) Medicaid VBPs for Patients (MVP) Act (H.R. 2666/S.4204) Accelerating Kids Access to Care Act (S. 2372)

Funding for federal hemophilia programs in FY25 House and Senate Labor-HHS Appropriations bills

Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Issues related to 1115 Waivers in Medicaid Preserving and expanding access to Medicaid Comments in response to CY 2025 Medicare Physician Fee Schedule Comments in response to CY 2025 Medicare HOPPS proposed rule

Implementation of the Affordable Care Act The HELP Copays Act (HR 830) Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model Policies related to copay accumulator adjustor and maximizer programs Issues related to 1332 state innovation waivers H.J. Res. 181, Congressional Review Act resolution to stop the Biden-Harris rule limiting access to Association Health Plans (AHPs) Healthcare Affordability Act of 2024 (H.R. 9774 / S. 5194) AIMED Alliance Citizens Petition re drug importation and alternative payment models

FY25 House and Senate Labor-HHS Appropriations bills

Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851/S. 2464) Safe Step Act (H.R.2630/S. 652) Implementation of the Affordable Care Act HELP Copays Act (H.R.830/S.1375) Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging Find It Early Act (H.R.3086/S.5141); a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Policies related to coverage of preventive services with no cost-sharing Polices regarding White House Cancer Moonshot implementation Policies related to copay accumulator and maximizer adjustors H.J. Res. 181, Congressional Review Act resolution to stop the Biden-Harris rule limiting access to Association Health Plans (AHPs) Policies related to the extension of enhanced advanced premium tax credits Healthcare Affordability Act of 2024 (H.R. 9774 / S. 5194) H.R. 1692 - Health Care Affordability Act of 2023; a bill to revise the tax credit for health care premium assistance to expand the eligibility of low-income taxpayers for such credit and reduce the cost of health care premiums S. 8 - Improving Health Insurance Affordability Act of 2023; a bill to expand the eligibility of taxpayers for the refundable tax credit for coverage under a qualified health plan and increases cost-sharing subsidies under the Patient Protection and Affordable Care Act

Outreach to the Dr. Bertagnolli, NIH Director, and the Office of the Director

Health disparities Access to clinical trials for underrepresented populations Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.3916/S.1840) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices, including comments on the proposed rule to regulate Medical Devices; Laboratory Developed Tests The Patent Eligibility Restoration Act (S.2140) Policies related to ICD-10 code for inflammatory breast cancer Comments in response to Congressional Next-Generation Cures package Comments in response to the House Energy & Commerce Committee Framework for Discussion on Reforming the National Institutes of HealthProhibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V) (CFPB-2024- 0023) Comments in response to Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies (FDA-2021D-0789)

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to access to supplemental and diagnostic breast imaging FY25 House and Senate Labor-HHS Appropriations bills (H.R. 9029/S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025) Policies related to report language on the implementation of the Medicare Prescription Payment Plan. Policies related to the transparent use of artificial intelligence, via patient notification, and validation of its use, scaling and outcomes in breast cancer screening.

CDCs Sickle Cell Disease Data Collection Program work with community-based organizations HHS Sickle Cell Disease Summit

Health disparities Access to clinical trials for underrepresented populations Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.3916/S.1840) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices, including comments on the proposed rule to regulate Medical Devices; Laboratory Developed Tests Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021, requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs (S.373/ H.R.4472) Palliative Care and Hospice Education Training Act (PCHETA) (S. 2243) The Patent Eligibility Restoration Act (S.2140) Policies related to ICD-10 code for inflammatory breast cancer

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to access to supplemental and diagnostic breast imaging FY24 House and Senate Labor-HHS Appropriations bills FY25 House and Senate Labor-HHS Appropriations bills Policies related to the transparent use of artificial intelligence, via patient notification, and validation of its use, scaling and outcomes in breast cancer screening.

Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851/S. 2464) Cancer Drug Parity Act (S. 2039) Telehealth Benefit Expansion for Workers Act (H.R. 824) Association Health Plans Act (H.R. 2868) Safe Step Act (H.R.2630/S. 652) Implementation of the Affordable Care Act Policies related to insurance coverage and COVID-19 HELP Copays Act (H.R.830/S.1375) Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging Issues related to regulation of short-term limited duration plans Implementation of the No Surprises Act, including comments on proposed rule re: Federal Independent Dispute Resolution Operations Find It Early Act (H.R.3086); a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Policies related to coverage of preventive services with no cost-sharing Polices regarding White House Cancer Moonshot implementation Policies related to copay accumulator adjustors Letter to Committee on Education and the Workforce Request for Information on Employer-Sponsored Insurance and Employee Retirement Income Security Act (ERISA)

H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act Outreach to the Dr. Bertagnolli, NIH Director, and the Office of the Director Outreach to the White House RE: Initiative on Women's Health Research

Implementation of the No Surprises Act Blood and plasma safety and awareness Bleeding disorders awareness Issues related to plasma donation in border states Issues related to access to residential substance use disorder and mental health facilities for individuals with bleeding disorders Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Menstrual Equity for All Act (H.R. 3646) Securing Equal Access to Research, Care, and Health (SEARCH) Act Creating Hope Reauthorization Act of 2024 (HR 7384)

FY24 House and Senate Labor-HHS Appropriations bills FY25 House and Senate Labor-HHS Appropriations bills

Hemophilia research, prevention, surveillance and service programs and issues H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act

Policies related to the orphan drug provision in the Inflation Reduction Act

CDCs Sickle Cell Disease Data Collection Program work with community-based organizations

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to access to supplemental and diagnostic breast imaging FY24 House and Senate Labor-HHS Appropriations bills FY25 House and Senate Labor-HHS Appropriations bills Policies related to the transparent use of artificial intelligence, via patient notification, and validation of its use, scaling and outcomes in breast cancer screening.

H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act Outreach to the Dr. Bertagnolli, NIH Director, and the Office of the Director Outreach to the White House RE: Initiative on Women's Health Research

Health disparities Access to clinical trials for underrepresented populations Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.3916/S.1840) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices, including comments on the proposed rule to regulate Medical Devices; Laboratory Developed Tests Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021, requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs (S.373/ H.R.4472) Palliative Care and Hospice Education Training Act (PCHETA) (S. 2243) The Patent Eligibility Restoration Act (S.2140) Policies related to ICD-10 code for inflammatory breast cancer

Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Implementation of the Hemophilia SNF Access Act Coverage for Telehealth Services Closing the Medicaid coverage gap Issues related to 1115 Waivers in Medicaid Medicaid unwinding, the process for redetermination of Medicaid eligibility Preserving and expanding access to Medicaid Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) PROTECT Rare Act (H.R. 6094) MVP Act (H.R. 2666) Comments Re: Medicaid; CMS Enforcement of State Compliance with Reporting and Federal Medicaid Renewal Requirements Under Section 1902(t) of the Social Security Act (CMS-2447-IFC) Comments RE: Notice of Benefit and Payment Parameters for 2025 Proposed Rule (CMS-9895-P). Comments Re: Proposed Rescission of Association Health Plan Final Rule (RIN 1210-AC16)

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Hemophilia research, prevention, surveillance and service programs and issues H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act

FY24 House and Senate Labor-HHS Appropriations bills FY25 House and Senate Labor-HHS Appropriations bills

Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (not yet introduced) Policies related to the social security disability programs, including letter to SSA seeking the review of the the disability criteria for sickle cell disease

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to access to supplemental and diagnostic breast imaging FY24 House and Senate Labor-HHS Appropriations bills Letter RE: House Budget Committees Health Care Task Force Request for Information on containing health care costs

H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act Letter regarding Request for Information on Modernizing the National Institutes of Health (NIH) Letter supporting the nomination of Dr. Bertagnolli to NIH Director

Health disparities Access to clinical trials for underrepresented populations Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.3916/S.1840) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices, including comments on the proposed rule to regulate Medical Devices; Laboratory Developed Tests Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021, requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs (S.373/ H.R.4472) Palliative Care and Hospice Education Training Act (PCHETA) (S. 2243) Comments in response to the discussion draft of the Stop Drug Shortages Act Letter to Congressional leadership related to drug shortages Letter in response to request for information on Modernizing the Centers for Disease Control and Prevention

FY24 House and Senate Labor-HHS Appropriations bills

Hemophilia research, prevention, surveillance and service programs and issues H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act Comments on: Modernizing Recalls of FDA-Regulated Commodities

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Comments on 503b facilities and compounding

Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Implementation of the Hemophilia SNF Access Act Coverage for Telehealth Services Closing the Medicaid coverage gap Issues related to 1115 Waivers in Medicaid Medicaid unwinding, the process for redetermination of Medicaid eligibility Preserving and expanding access to Medicaid Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) PROTECT Rare Act (H.R. 6094) MVP Act (H.R. 2666)

FY24 House and Senate Labor-HHS Appropriations bills

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Comments in response to Congressional RFI on 340B Program Response to FDA Guidance re Decentralized Clinical Trials Comments on 503b facilities and compounding

Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Implementation of the Hemophilia SNF Access Act Coverage for Telehealth Services Closing the Medicaid coverage gap Issues related to 1115 Waivers in Medicaid Medicaid unwinding, the process for redetermination of Medicaid eligibility Preserving and expanding access to Medicaid Comments in response to the Medicare CY24 Physician Fee Schedule Proposed Rule Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996)

Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851/S. 2464) Cancer Drug Parity Act (S. 2039) Telehealth Benefit Expansion for Workers Act (H.R. 824) Association Health Plans Act (H.R. 2868) Safe Step Act (H.R.2630/S. 652) Implementation of the Affordable Care Act Policies related to insurance coverage and COVID-19 HELP Copays Act (H.R.830/S.1375) Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging Issues related to regulation of short-term limited duration plans Implementation of the No Surprises Act Find It Early Act (H.R.3086); a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Policies related to coverage of preventive services with no cost-sharing Polices regarding White House Cancer Moonshot implementation

H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act

Metastatic Breast Cancer Access to Care Act (S. 663 / HR 549) Reducing Hereditary Cancer Act (HR 1526/S. 765) CONNECT for Health Act (H.R. 4189/S. 2016) Medicare coverage policy for breast cancer treatments and services Telehealth Policies related to funding, state incentives, and federal efforts for Medicaid expansion Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Policies related to Medicare coverage for pharmacy services Medicare coverage policy for drugs and drug pricing H.R. 9505 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Medicaid unwinding, the process for redetermination of Medicaid eligibility Medicare Drug Pricing Negotiation implementation Implementation of Lymphedema Treatment Act Preserving and expanding access to Medicaid Comments in response to the Medicare CY24 Physician Fee Schedule Proposed Rule Comments in response to the Medicare CY24 Hospital Outpatient Prospective Payment System Comments in response to Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements (CMS-1780-P) Comments in response to Solicitation of Comments on Maximum Monthly Cap on Cost-Sharing Payments Under Prescription Drug Plans: Draft Part One Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025 Comments in response to CMS-2434-P; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to access to supplemental and diagnostic breast imaging FY24 House and Senate Labor-HHS Appropriations bills

Metastatic Breast Cancer Access to Care Act (S. 663 / HR 549) Reducing Hereditary Cancer Act (HR 1526/S. 765) CONNECT for Health Act Medicare coverage policy for breast cancer treatments and services Telehealth Policies related to funding, state incentives, and federal efforts for Medicaid expansion Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Policies related to Medicare coverage for pharmacy services Medicare coverage policy for drugs and drug pricing H.R. 9505 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Medicaid unwinding, the process for redetermination of Medicaid eligibility Medicare Drug Pricing Negotiation implementation Implementation of Lymphedema Treatment Act Preserving and expanding access to Medicaid Policy related to medical billing for breast reconstruction surgery called DIEP flap, a type of natural tissue breast reconstruction that uses tissue from the lower abdomen to create a new breast

Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851) Safe Step Act (H.R.2630/S. 652) Implementation of the Affordable Care Act Policies related to insurance coverage and COVID-19 HELP Copays Act (H.R.830/S.1375) Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging Issues related to regulation of short-term limited duration plans Implementation of the No Surprises Act Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Comments in response to HCPCS coding policy regarding DIEP-flap procedures Comments in response to USPSTF revised recommendations for breast cancer screening Policies related to coverage of preventive services with no cost-sharing Polices regarding White House Cancer Moonshot implementation

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Comments in response to Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products

FY24 House and Senate Labor-HHS Appropriations bills

Hemophilia research, prevention, surveillance and service programs and issues Comments in response to Congressional RFI re CDC

Access to Breast Cancer Diagnosis (ABCD) Act Safe Step Act (S. 652) Implementation of the Affordable Care Act Policies related to insurance coverage and COVID-19 HELP Copays Act (H.R.830) Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging Issues related to regulation of short-term limited duration plans Implementation of the No Surprises Act Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Comments in response to proposed 2024 Notice of Benefit and Payment Parameters Policies related to coverage of preventive services with no cost-sharing Polices regarding White House Cancer Moonshot implementation

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to access to supplemental and diagnostic breast imaging FY24 House and Senate Labor-HHS Appropriations bills

Health disparities Access to clinical trials for underrepresented populations Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021, requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs (S.373/ H.R.4472)

Hemophilia research, prevention, surveillance and service programs and issues

FY24 House and Senate Labor-HHS Appropriations bills Appropriations for the National Hemophilia Program at HRSA Appropriations for Hemophilia Activities and Hemophilia Treatment Centers at CDC

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Comments in response to Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry

FDA policies related to research and approvals of treatments for hematological diseases

Issues related to mifepristone

Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum Graduate medical education Comments in response to the RFI regarding accessing healthcare and related challenges, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency (PHE)

H.R. 2617 - Consolidated Appropriations Act of 2023; Breast cancer research at the Department of Defense H.R. 7900 - National Defense Authorization Act for Fiscal Year 2023; a bill to authorize Department of Defense activities and programs for FY 2023

Metastatic Breast Cancer Access to Care Act (S. 1312 / HR 3182) Multi-Cancer Early Detection Screening Coverage Act (HR 1946/S 1873) Lymphedema Treatment Act (HR 3630/ S 1315) Breast Cancer Patient Equity Act (HR 3087/S 2051) Reducing Hereditary Cancer Act of 2021 (HR 4110) CONNECT for Health Act (S.1512/ H.R. 2903) Improving Seniors' Timely Access to Care Act (H.R.3173) Comprehensive Breast Reconstruction Act of 2021 (H.R. 469) Seniors Prescription Drug Relief Act (S.2327) Medicare coverage policy for breast cancer treatments and services Radiation Oncology Alternative Payment Model Telehealth Policies related to funding, state incentives, and federal efforts for Medicaid expansion Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Policies related to Medicare coverage for pharmacy services and the Equitable Community Access to Pharmacist Services Act (H.R.7213) Medicare coverage policy for drugs and drug pricing H.R. 9505 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Comments regarding the temporary increase in federal medical assistance percentage (FMAP) in response to the COVID-19 Public Health Emergency (PHE) (CMS-9912-N) Comments in response to the Medicaid Eligibility and Enrollment NPRM (CMS-2421-P) Comments in response to the RFI regarding National Directory of Healthcare Providers & Services (CMS-0058-NC) Comments in response to the RFI regarding accessing healthcare and related challenges, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency (PHE)

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to development of the Advanced Research Projects Agency for Health H.R. 2617 - Consolidated Appropriations Act of 2023

Making Advances in Mammography and Medical Options for Veterans Act (S.2533/H.R.4794) H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021

Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2022 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Protect 340B Act (HR 4390) Prescription Drug User Fee Amendments Citizens Petition regarding gene therapy in hemophilia

Implementation of the Affordable Care Act The HELP Copays Act (HR 5801) Policies related to insurance coverage and COVID-19 Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model Safe Step Act (HR 2163 / S 464) Policies to make Advance Premium Tax Credits Permanent Implementation of the No Surprises Act Policies related to short-term, limited duration insurance Comments in response to the RFI on Advanced Explanation of Benefits and Good Faith Estimate for Covered Individuals (CMS9900-NC) Section 1557, Nondiscrimination in Health Programs and Activities (RIN Number 0945-AA17) Request for Information on establishing a National Directory of Healthcare Providers and Services

H.R. 2617 - Consolidated Appropriations Act of 2023 Funding for federal hemophilia programs in FY 22 Labor, HHS, and Education Appropriations Policies related to paid family and medical leave

Health disparities Access to clinical trials for underrepresented populations Improving Social Determinants of Health Act (S.104/H.R.379) Comprehensive Breast Reconstruction Act of 2021 (H.R. 469) DIVERSE Trials Act (H.R. 5030/S. 2706) Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R.6584); a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes CURES 2.0 Act (H.R. 6000) Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Policies related to reauthorization of user fees at the Food and Drug Administration (H.R. 7667/ S. 4348) H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 Advanced Research Project Agency-Health Act (H.R.5585) Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act (S.3799) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017

Access to Breast Cancer Diagnosis (ABCD) Act (S. 1067/ H.R. 5769) Metastatic Breast Cancer Access to Care Act (S. 1312 / HR 3182) Cancer Drug Coverage Parity Act (HR 4385) Protecting Access to Lifesaving Screening (PALS) Act(HR 4612/S.2412) Safe Step Act (H.R. 2163/S. 464) The Closing Health Coverage Gaps for Public Servants Act (H.R. 7045/S. 3796) Implementation of the Affordable Care Act Implementation of the No Surprises Act Policies related to insurance coverage and COVID-19 Junk Plan Accountability and Disclosure Act (S. 1002) No Junk Plans Act (S. 942) HELP Copays Act (H.R.5801), accumulator adjustor issues Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Policies regarding White House Cancer Moonshot implementation Issues related to regulation of short-term limited duration plans H.R. 5376 - Inflation Reduction Act of 2022; a budget reconciliation bill which included provisions to continue subsidies on private insurance premiums, address out of pocket costs in Medicare Part D, and more Comments on future rulemaking for the 2024 Notice on Benefit and Payment Parameters

Making Advances in Mammography and Medical Options for Veterans Act (S.2533/H.R.4794) H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021

Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Protect 340B Act (HR 4390) Prescription Drug User Fee Amendments Citizens Petition regarding gene therapy in hemophilia

Implementation of the No Surprises Act Blood and plasma safety and awareness Bleeding disorders awareness Issues related to plasma donation in border states

Hemophilia research, prevention, surveillance and service programs and issues

Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations report language related to metastatic breast cancer Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to paid family and medical leave Policies related to development of the Advanced Research Projects Agency for Health Supplemental appropriations for COVID-19-related relief, the production of monoclonal antibodies, availability of testing, etc Addition in any reconciliation package of policies related to health insurance coverage and affordability, including permanent extension of Advanced Premium Tax Credits provided by the American Rescue Plan, closing the Medicaid coverage gap, and a cap on out-of-pocket costs for Medicare Part D beneficiaries Appropriation for Consumer Assistance Programs (CAPs)

Breast cancer research at the Department of Defense H.R. 7900 - National Defense Authorization Act for Fiscal Year 2023; a bill to authorize Department of Defense activities and programs for FY 2023

Making Advances in Mammography and Medical Options for Veterans Act (S.2533/H.R.4794) H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021

Health disparities Access to clinical trials for underrepresented populations Improving Social Determinants of Health Act (S.104/H.R.379) Comprehensive Breast Reconstruction Act of 2021 (H.R. 469) DIVERSE Trials Act (H.R. 5030/S. 2706) Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R.6584); a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes CURES 2.0 Act (H.R. 6000) Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Policies related to reauthorization of user fees at the Food and Drug Administration (H.R. 7667/ S. 4348)H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 Advanced Research Project Agency-Health Act (H.R.5585) Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act (S.3799) Comments to the FDA on Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry (FDA-2021-D0789) Comments to the FTC on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers (FTC-2022-0015)

FDA policies related to research and approvals of treatments for hematological diseases FDA-2021-D-0789 - Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry Draft Guidance for Industry - Considerations for the Development of Chimeric Antigen Receptor T Cell Products (Docket No. FDA-2021-D-0404) Comments to the FTC on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers (FTC-2022-0015)

FY 2023 House and Senate Labor HHS Appropriations bills Funding for CDC Sickle Cell Disease Data Collection Program and HRSA Sickle Cell Disease Regional Demonstration Program Funding for Hematology research and NIH total funding

Implementation of the No Surprises Act Blood and plasma safety and awareness Bleeding disorders awareness Issues related to plasma donation in border states

Funding for federal hemophilia programs in FY 22 Labor, HHS, and Education Appropriations Build Back Better Act (HR 5376) Policies related to paid family and medical leave Appropriation for Consumer Assistance Programs (CAPs)

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program Protect 340B Act (HR 4390) Comments to the FTC on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers (FTC-2022-0015) Prescription Drug User Fee Amendments FDA-2021-D-0398; Human Gene Therapy Products Incorporating Human Genome Editing FDA-2021-D-0789 - Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry HR 4390 - Protect 340B Act

Hemophilia research, prevention, surveillance and service programs and issues